Pharmanutra CS - Prime Vendite SUL Mercato Americano Stock: price and insider trades · Italy
Pharmanutra CS - Prime Vendite SUL Mercato Americano: what insiders have been doing
Pharmanutra CS - Prime Vendite SUL Mercato Americano has a thin disclosure history in our data (latest filing: 3 October 2023). New filings will appear here as soon as they are published. Every figure here comes from the filings published by Consob and describes the past, not future prices; it is not investment advice.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 8,005 of 26,911 companies
61.7
score / 100
Value38
Quality85
FCF yld2.1%
Earn yld2.6%
EV/EBITDA23.5x
ROE30%
Gross mgn77%
Net mgn15%
Debt/EBITDA0.6x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€81.90
Analyst consensus
3 analysts1.00/5
€76.00Target €81.33(-1%)€86.00
Income statement
Revenue€132.9M
Gross profit€102.9M77% margin
EBITDA€34.3M26% margin
Net income€20.0M15.1% margin
Valuation
PER (trailing)37.2x
PER (forward)26.7x
P/Book10.6x
Beta0.17
Balance sheet & cash
Market cap€784.2M
Total debt€20.5M
Free Cash Flow€16.4M
Debt / Equity26%
Profitability & ownership
ROE30.1%
ROA15.2%
% insiders65.0%
% institutions17.2%
Last declaration on 3 October 2023
Declarations1 total
- ●Executives0Consob
1 of 1 declaration
About Pharmanutra CS - Prime Vendite SUL Mercato Americano
Pharmanutra CS is a company specialized in the health and pharmaceutical sector, focusing on selling its products in the American market. It is listed on the XMIL market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
